Human platelets stimulated by epinephrine undergo enhanced turnover of phosphatidylinositol 4,5-bisphosphate, accumulate inositol trisphosphate, diacylglycerol, and phosphatidic acid, and phosphorylate a 47-kDa protein.
increased turnover of ester-linked arachidonic acid in aspirintreated platelets that is inhibited by ONO-RS-082, EDTA, yohinbine, or the absence of fibrinogen and (ii) a rapid cytoplasmic alkalinization that is inhibited partially by blockage of cyclooxygenase activity and completely by A2A9 or EIPA. In contrast, when incubated with subaggregatory concentrations of the prostaglandin H2/thromboxane A2 analogue [(15S)-hydroxy-1 ia,9a-(epoxymethano)prosta-5,13-dienoic acid (U46619) and epinephrine, aspirin-treated platelets show a potentiation of phospholipase C activation that is unaffected by the above inhibitors. We propose that epinephrine, in promoting exposure of glycoprotein Ilb/ia sites for fibrinogen binding, leads to a cytoplasmic alkalinization, which, in conjunction with local shifts in Ca2 , promotes low-level activation of phospholipase A. The resulting free arachidonic acid is converted to cyclooxygenase products, which, potentiated by epinephrine, activate phospholipase C. This further amplifies the initial stimulatory response.
Human platelets undergo aggregation and secretion of granule contents following exposure to epinephrine in the presence of fibrinogen and Ca2". Accompanying such activation is an enhanced turnover of phosphatidylinositol catalyzed by phospholipase C (PLC), indicated in earlier studies by stimulated incorporation of [3H]glycerol (1, 2) , diacylglycerol accumulation, and activation of protein kinase C (3). However, human platelet adrenergic receptors have been characterized as being primarily of the a2 subclass (4, 5) , which, in other tissues, is not linked with phosphatidylinositol phosphate turnover (6) .
A resolution of this paradox may lie in a report that epinephrine-stimulated generation of [32P]phosphatidic acid (PtdOH), an indirect indicator of PLC activation, can be inhibited by aspirin (7) . This implies a possible role for the cyclooxygenase-catalyzed oxygenation of arachidonic acid in mediating the process of PLC activation in response to epinephrine. Recently, investigators have found that epinephrine promotes arachidonic acid mobilization (a precondition for cyclooxygenase action) in a manner dependent upon Na+/H+ exchange (8) . This mobilization was quantitated by measuring thromboxane B2 (TXB2), the stable metabolite of thromboxane A2, which is, in turn, formed by way of cyclooxygenase. Clearly, to sort out epinephrine-initiated events from those resulting from the action of stimulatory cyclooxygenase metabolites, it is necessary to characterize those events that occur in the presence of cyclooxygenase inhibitors, such as aspirin. One such change elicited by epinephrine even in the presence of aspirin is a shift in the conformation of glycoprotein Ilb/Ila (GPIIb/IIIa) complex on the platelet surface (9, 10) that facilitates the binding of fibrinogen (11, 12) . Another observation is that epinephrine potentiates the aggregatory response of aspirin-treated platelets exposed to subthreshold levels of other agonists, such as TXA2/prostaglandin H2 (PGH2) analogues (13) . Therefore, we hypothesized that the binding of epinephrine to the platelet surface might evoke a mobilization ofarachidonic acid independently (at least initially) of any involvement of PLC. The oxygenation of arachidonic acid to PGH2 and TXA2 would then provide receptor-directed agonists capable of activating PLC (14) . Such activation could be potentiated by epinephrine, leading to an amplified response, including further release of arachidonate. In testing this hypothesis, we have investigated the roles of Na+/H+ exchange and occupancy of GPIIb/IIIa by fibrinogen in the initiation and potentiation processes.
MATERIALS AND METHODS
Preparation of Platelets. Human platelet-rich plasma, free of erythrocytes, was prepared as described (15) in the presence of 0.5 ,M prostaglandin E1 (Upjohn) and spun at 3000 x g x 5 min at room temperature. Platelets were suspended in 4 ml of 20% plasma/80% gel-filtration buffer (GFB) (pH 6.5) (14) containing 0.1% gelatin and creatine phosphate (5 mM)/creatine phosphokinase (40 units/ml). For labeling with 32P and/or [3H]arachidonic acid, the platelets were incubated as described (14) (15) . The aqueous phases of the extracts were assayed for TXB2 by radioimmunoassay (Upjohn). In some experiments, fibrinogen was replaced by or added with A2A9 (40 gg/ml), a monoclonal antibody against GPIIb/IIIa complex that binds equally well to resting and stimulated platelets, prepared as described (9, 10 Phosphatidylinositol Phosphate Turnover, Protein Phosphorylation, and Secretion. Platelets labeled with 3H or 32p were incubated as above in an aggregometer with and without aspirin (1 mM) for 15 min, followed by epinephrine. Aliquots were removed at various times for electrophoresis on 11% NaDodSO4/polyacrylamide gels, as described before (16) , or extraction and thin-layer chromatography (14) . When myoinositol trisphosphate (InsP3) was to be quantitated, unlabeled platelets were incubated in 10-ml cuvettes such that aliquots containing 3 x 109 platelets could be removed and extracted (17) . InsP3 was quantitated by capillary gas chromatography (17, 18) . Secretion of dense granule substituents was monitored by the release of [14C]serotonin from platelets (14) .
Potentiation Studies._32P-labeled platelets, exposed to aspirin, were incubated at 37°C for 4 min in the presence of Ca2+, fibrinogen, and/or A2A9. ONO-RS-082 or EIPA was also included where appropriate. Subaggregatory concentrations of (1SS)-hydroxy-lla,9a-(epoxymethano)prosta-5,13-dienoic acid [(U46619) a stable thromboxane receptor agonist; Upjohn] were determined for each preparation of platelets following dose-response assays. The platelets were then mixed with such concentrations of U46619, epinephrine (100 ,M), both, or neither, for 75 s. The reaction was determined and products were resolved as above.
Arachidonic Acid Turnover. 3H-labeled platelets were exposed to aspirin or buffer and incubated as above in the presence of 0.05% delipidated albumin, with and without epinephrine (100 ,uM) for up to 10 min. Incubations were terminated and supernatants containing [3H]arachidonic acid were resolved by HPLC as described (19) . Fractions containing arachidonic acid and 12-hydroxyicosatetraenoic acid (12-HETE) were either assayed by scintillation spectrophotometry or dried, derivatized (20) , and quantitated by capillary gas chromatography on a CP Sil88 column (Chrompack) in a Hewlett-Packard 5880A gas chromatograph at 1750C (injection, 200'C; detector, 200'C; flow, 2.43 ml/min; split, 50:1). In aspirin-free platelets, maximum 12-HETE formation occurred 5 min after the addition of epinephrine (40 ng per 109 platelets). However, since no rise in arachidonic acid (or 12-HETE) was observed in response to epinephrine/aspirin, studies were undertaken to detect accelerated turnover of arachidonate. For "cold chase" experiments, [3H]arachidonic acid/32P-labeled platelets, treated with aspirin, were incubated for 10 s with epinephrine (50 A.M) in the presence of fibrinogen (200 tug/ml) and Ca2l (0.5 mM) and then exposed to ethanol vehicle (0.1%) or unlabeled arachidonic acid (1 or 10 uM) for 120 s. Aspirin completely inhibited all cyclooxygenase activity, as gauged by failure of treated platelets to aggregate in response to 3 1LM arachidonate or form TXB2. In some studies, buffer was substituted for epinephrine or fibrinogen, or 1 mM EDTA replaced Ca2', or the a2-antagonist yohimbine (10 ,uM; Sigma) was present. Incubations were stopped with CHCl3/MeOH/HCl (1:2:0.02), and lipids were resolved and quantitated (15) . The effects of epinephrine on incorporation of [3H]arachidonic acid into phospholipid were also measured. Aspirin-treated platelets were incubated as above with and without epinephrine. After 10 s, 9 nM [3H]arachidonic acid was added. In one study, ONO-RS-082 (3.5 ,uM) was included. Aliquots were removed after different times and lipids were resolved by twodimensional silicic acid paper chromatography (21) .
Cytoplasmic Alkalinization. The changes in intracellular pH of human platelets in response to epinephrine were measured essentially as described (22) . Filtered platelets (109 per ml)
were allowed to equilibrate with 9-aminoacridine (4 ,uM; Sigma) in the presence of Ca2+ and fibrinogen or A2A9 for 4 min in a Perkin-Elmer 650-1OS spectrofluorimeter equipped with thermostating and stirring devices. The fluorescence was monitored continuously (Xex = 400 nm; Xem = 456 nm). When the fluorescence reached a constant level, epinephrine or monensin was added and the change in fluorescence was monitored. The change in transmembrane pH gradient, 8(ApH), was calculated as described (22) . Aspirin was found to interfere with uptake of 9-aminoacridine and fluorescence measurements. Therefore, indomethacin was substituted and the cells were allowed to equilibrate with 9-aminoacridine before adding 2 jig of indomethacin per ml. This was sufficient to block conversion of 3 ,uM arachidonic acid to TXB2. After 3 min, epinephrine and/or U46619 were added and the change in fluorescence was monitored as above. In some -experiments, A2A9, EIPA, or creatine phosphate/ creatine phosphokinase was added 3 min prior to epinephrine. In all experiments, aggregation in response to epinephrine was closely monitored and used as an index of platelet "responsiveness," which was unimpaired by 9-aminoacridine.
RESULTS AND DISCUSSION
The studies to be described establish four sequential phases of human platelet activation in response to a2-adrenergic stimulation: (0) activation of Na+/H+ exchange (alkalinization) that is dependent upon the binding of fibrinogen to receptive GPIIb/IIIa complexes, (it) mobilization of arachidonic acid by PLA2 in a manner partially dependent upon Na+/H+ exchange, (iii) conversion of arachidonic acid to PGH2/TXA2, thereby initiating the activation of PLC, and (iv) potentiation of the activation of PLC. The fourth, potentiating, phase can be mimicked by epinephrine and low concentrations of the PGH2/TXA2 analogue U46619 and is independent of fibrinogen binding, Na+/H+ exchange, and PLA.
The factors affecting platelet cytoplasmic alkalinization are represented graphically in Fig. 1 (2 ,ug/ml) were determined. Fluorescence of 9-aminoacridine was measured before and after the addition of stimulus (A, = 400 nM; Aem = 456 nM). ApH was calculated as described (22 Fig. 2 ). Sweatt et al. (8) have reported that omission of Na' (which also prevents Na+/H' exchange) blocks TXB2 formation by inhibiting the release of arachidonic acid rather than by inhibiting cyclooxygenase, since it does not interfere with the conversion of arachidonic acid to TXB2. As seen in Table 1 , the stimulated increases in TXB2 are also inhibited by A2A9, which, as noted above, decreases fibrinogen/GPIIb/IIIa complex formation and cytoplasmic alkalinization, and by ONO-RS-082, an agent that impairs PLA activity. We have found that neither of these agents blocks conversion of arachidonic acid to TXB2; therefore they must be acting at the level of arachidonic acid release. In parallel, formation of [32P]PtdOH, a sensitive monitor of PLC activation, is also inhibited by EIPA, A2A9, and ONO-RS-082. These findings are consistent with a role for TXA2 in mediating the activation of PLC (see also Fig. 2) . We have found that none of these inhibitors interferes with the formation of PtdOH induced by U46619, an agonist that, as an analogue of TXA2, bypasses the need for arachidonic acid mobilization and TXA2 formation. Further, from these observations we know that the inhibitors block neither diacylglycerol kinase (required for PtdOH synthesis from diacylglycerol) nor PLC (which forms diacylglycerol).
We have attempted to quantitate arachidonic acid release (or lysophospholipid formation) in aspirin-treated platelets exposed to epinephrine, using HPLC, thin-layer chromatography, and gas chromatography, but without success. No statistically significant release is observed, despite increases in TXB2 and 12-HETE in aspirin-free platelets exposed to epinephrine. It seemed possible that, in the absence of cyclooxygenase activity to convert arachidonic acid to its metabolites, the small amounts of arachidonic acid released might be reincorporated rapidly into phospholipids. It is unlikely that this arachidonic acid would be used by lipoxygenase, which requires substantially more availability of arachidonic acid than does cyclooxygenase (24) , and, in fact, we detect no rise in 12-HETE under these conditions. We therefore have employed two approaches to detect arachidonic acid turnover in phospholipid, examining the effects of epinephrine on (t) incorporation of [3H]arachidonic acid (trace levels) into phospholipid and (il) mobilization of [3H]arachidonic acid from phospholipid in prelabeled platelets, using unlabeled arachidonic acid. Epinephrine enhances uptake of [3H]arachidonic acid into several classes of phospholipid 1.5-to 2-fold in 60 s (not shown). The PLA inhibitor ONO-RS-082 inhibits this uptake. Such platelets undergo a low level ("primary wave") of aggregation but do not secrete storage pool components such as ADP.
Epinephrine also enhances the replacement of labeled arachidonic acid by unlabeled arachidonic acid in a manner dependent upon fibrinogen, divalent cation, and a2 receptor occupancy ( Table 2) . Levels of 32p in phospholipid are Platelets were stirred in an aggregometer with Ca2+ and fibrinogen (200 ,ug/ml) in the presence or absence of A2A9 (100 ,ug/ml), ONO-RS-082 (3.5 ,uM), or EIPA (40 ALM) for 4 min, followed by epinephrine or buffer for 75 s. Results are expressed as the % of epinephrine-free controls and represent the mean ± SEM. ND, not determined. (Fig. 2, solid lines) . These changes are blocked completely by aspirin (Fig. 2, broken lines) or indomethacin (not shown). Inhibition cannot be overcome by up to 500 ,uM epinephrine. Although not clearly evident here, a small wave of aggregation does occur in aspirin-treated platelets, but secretion (ordinarily 68% ± 4% SEM of the total storage pool after a 120-s exposure to epinephrine) is prevented completely by aspirin. We have also observed that the presence of yohimbine or omission of fibrinogen will block these changes equally effectively. Finally, despite the lack of measurable kinase C activation in aspirin-treated platelets exposed to epinephrine, we know from the foregoing results that alkalinization can occur. Thus, in contrast to the case for other systems (25) , kinase C is not necessary for initiation of this event.
The function of epinephrine in potentiating PLC activation in response to U46619 (and presumably PGH2/TXA2) is distinct from that as a promoter of PLA activation in the sequence described above. Aspirin-treated platelets show no rise in the mass of InsP3 in response to epinephrine above basal levels of 40 pmol per 109 platelets (Fig. 2) and a slight rise in response to 7.5 nM U46619 (137% of control in 60 s; 159% in 90 s). In the presence of epinephrine plus 7.5 nM or buffer were added. Aliquots were removed after various times for resolution and quantitation of phosphorylated protein (A) or phosphatidylinositol phosphate and metabolites (B and C). Aggregation was followed simultaneously (C). Ptdlns (4, 5) Recently, investigators have demonstrated that the epinephrine-induced opening of GPIIb/IIIa binding sites for fibrinogen is dependent upon environmental ADP (26) . Epinephrine enhances the binding of ADP to its receptor 10-fold (26) , and it has been reported elsewhere (8) that ADP-induced arachidonic acid mobilization is inhibited by EIPA. Preliminary studies examining the effects of creatine phosphate/ creatine phosphokinase (to remove ADP) on platelet activation by epinephrine have yielded variable results. Inhibition of alkalinization is observed (for example, see Fig. 1 ) but is not always complete. Further experiments, most probably with specific receptor-directed inhibitors, are needed to resolve this point definitively. However, given that Na+/H' exchange appears to be dependent upon the binding of fibrinogen to GPIIb/IIIa, if exposure of cryptic GPIIb/IIIa complex is a function of ADP binding, it follows that alkalinization should also be a function of ADP binding. In such a case, activation of PLA would be dependent upon epinephrine-potentiated ADP binding, and PLC activation would be dependent upon epinephrine-potentiated TXA2 effects. A scheme summarizing our findings and the possible role of ADP is presented in Fig. 3 . The mechanisms by which epinephrine acts as a potentiator independently offibrinogen, Na+/H+ exchange, and PLA and as a mobilizer of Ca2+ independently ofphosphatidylinositol phosphate metabolism are important subjects for future study.
